Department of Biochemistry and Molecular Cell Biology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, China.
Research Center for Translational Medicine, East Hospital, TongJi University School of Medicine, Shanghai, China.
FEBS J. 2019 Nov;286(21):4160-4175. doi: 10.1111/febs.15028. Epub 2019 Aug 22.
Tumor immunotherapy has achieved remarkable efficacy, with immune-checkpoint inhibitors as especially promising candidates for cancer therapy. However, some issues caused by immunotherapy have raised attention, such as limited efficacy for some patients, narrow antineoplastic spectrum, and adverse reactions, suggesting that using regulators of tumor immune response may prove to be more complicated than anticipated. Current evidence indicates that different factors collectively constituting the unique tumor microenvironment promote immune tolerance, and these include the expression of co-inhibitory molecules, the secretion of lactate, and competition for nutrients between tumor cells and immune cells. Furthermore, cancer-associated fibroblasts, the main cellular components of solid tumors, promote immunosuppression through inhibition of T cell function and extracellular matrix remodeling. Here, we summarize the research advances in tumor immunotherapy and the latest insights into the influence of microenvironment on tumor immunotherapy.
肿瘤免疫疗法已取得显著疗效，免疫检查点抑制剂作为癌症治疗的有前途的候选药物。然而，免疫疗法引起的一些问题引起了关注，例如对某些患者的疗效有限、抗肿瘤谱狭窄和不良反应，这表明使用肿瘤免疫反应调节剂可能比预期的更复杂。目前的证据表明，构成独特肿瘤微环境的不同因素共同促进免疫耐受，包括共抑制分子的表达、乳酸的分泌以及肿瘤细胞和免疫细胞之间的营养竞争。此外，癌症相关成纤维细胞是实体瘤的主要细胞成分，通过抑制 T 细胞功能和细胞外基质重塑来促进免疫抑制。在这里，我们总结了肿瘤免疫治疗的研究进展和对肿瘤免疫治疗中微环境影响的最新见解。
